decisionhealth Newsletters, Part B News - 2022 Issue 2 (February)
Negative results: Urine drug test denials hold bad news for family practices
Subscribe or sign in to view the full article.
Article Overview
This article reviews Medicare changes to urine drug testing coding and analyzes recent denial trends using claims data. It is relevant to family medicine, laboratory and pathology-related billing, and coding professionals who need to understand how urine drug testing services have been categorized and how denial patterns may affect reporting and reimbursement oversight. The discussion focuses on broad policy history, service categories, and specialty-level claim behavior rather than detailed coding instructions.
Why This Topic Matters
Urine drug testing continues to be an area of payer scrutiny, and denial trends can signal compliance risk, documentation concerns, or future audit activity for practices that bill these services.
What You Will Learn
- How Medicare’s urine drug testing code structure has changed over time
- How the article frames presumptive versus definitive drug testing
- What the claims data show about denial trends over several years
- Why denial patterns may be especially relevant for family practice providers
Who Should Read This
- Medical coders
- Billing specialists
- Family practice administrators
- Compliance staff
- Revenue cycle professionals
Codes Discussed
Code Ranges Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com